BioSpace News Archive

Data from AiKidney Helps Clinicians Gain New Insights into Patient’s Risk of Allograft Rejection.

Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 11:00 a.m. ET in New York.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET.

TRACON Pharmaceuticals announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 11:00 am Eastern Time.

Gritstone bio, Inc., a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, announced that the company has been certified as a Great Place to Work by the Great Place to Work® Institute.

OPKO Health, Inc. announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10, 2022 in New York City.

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, will host a global webcast to discuss new data from 1st line non-small cell lung cancer (NSCLC) patients participating in its Phase II TACTI-002 trial including an analyst Q&A.

Gain Therapeutics, Inc. announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place June 8-10 in New York, NY.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a trial to investigate the ERK1/2 inhibitor ERAS-007 in combination with a KRAS G12C inhibitor in KRAS G12C-driven non-small cell lung cancer and colorectal cancer.